• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aardvark Therapeutics, Inc. - Common Stock (NQ:AARD)

    10.38 +0.46 (+4.69%)
    Streaming Delayed Price Updated: 3:11 PM EST, Nov 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Aardvark Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
     
    Via Benzinga
    News headline image
    Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
    Aardvark to host Investor Webinar with members of the management team, leading key opinion leaders and patient advocates on November 5, 2025 
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
    Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient Population 
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Coinbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
     
    Via Benzinga
    News headline image
    Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Aardvark Therapeutics Reports Q2 Loss ↗
    Via The Motley Fool
    News headline image
    Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress ↗
    Aardvark's lead drug ARD-101 targets PWS and HO with trials underway and funding secured through 2027 after a $94.2 million IPO in February. 
    Via Benzinga
    Topics Initial Public Offering
    News headline image
    Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are gapping in today's session ↗
    Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
    Via Chartmill
    News headline image
    Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
    From Aardvark Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher ↗
    The drug treats excessive hunger that often leads to obesity in patients with a rare, genetic disease. 
    Via Investor's Business Daily
    News headline image
    This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
     
    Via Benzinga
    News headline image
    Kestra Opens For Trading, Discord Discusses Potential IPO ↗
    Shares of Kestra Medical, a wearable cardiac device maker, soared in the company's public debut this week. Meanwhile, Discord is said to be in talks for a possible IPO in 2025. 
    Via Talk Markets
    Topics Initial Public Offering Stocks / Equities
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.